Sanofi reports positive data from Phase II asthma treatment trial
The trial met the primary endpoint with high and low doses of rilzabrutinib leading to a numerical decrease in LOAC events.
The trial met the primary endpoint with high and low doses of rilzabrutinib leading to a numerical decrease in LOAC events.
The study will take place at Harvard’s Brigham and Women's Hospital and will validate AiM’s robot for deep brain stimulation in Parkinson’s.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
HeartBeam’s AI device outperforms experts in detecting atrial flutter
UK clinical trials industry tackles recent changes in the sector
AstraZeneca’s Phase III Covid-19 antibody trial meets primary endpoints
Allucent receives grant for decentralised Covid-19 vaccine trial